Page 130 - IMO-1-1

Innovative Medicines & Omics Promising molecule against SARS-CoV-2 nucleocapsid

doi: 10.1038/s41579-023-00878-2 13. Berman HM, Battistuz T, Bhat TN, et al. The protein data
bank. Acta Crystallogr D Biol Crystallogr. 2002;58(6):899-907.
2. Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2
variant biology: Immune escape, transmission and fitness. doi: 10.1107/S0907444902003451
Nat Rev Microbiol. 2023;21(3):162-177. 14. Ye Q, West AM, Silletti S, Corbett KD. Architecture and self-
doi: 10.1038/s41579-022-00841-7 assembly of the SARS-CoV-2 nucleocapsid protein. Protein
Sci. 2020;29(9):1890-1901.
3. Tan ST, Kwan AT, Rodríguez-Barraquer I, et al. Infectiousness
of SARS-CoV-2 breakthrough infections and reinfections doi: 10.1002/pro.3909
during the omicron wave. Nat Med. 2023;29(2):358-365. 15. Trott O, Olson AJ. AutoDock Vina: Improving the speed
doi: 10.1038/s41591-022-02138-x and accuracy of docking with a new scoring function,
efficient optimization, and multithreading. J Comput Chem.
4. Yu H, Guan F, Miller H, Lei J, Liu C. The role of SARS-CoV-2 2010;31(2):455-461.
nucleocapsid protein in antiviral immunity and vaccine
development. Emerg Microbes Infect. 2023;12(1):e2164219. doi: 10.1002/jcc.21334
+
doi: 10.1080/22221751.2022.2164219 16. Laskowski RA, Swindells MB. LigPlot : Multiple ligand-
protein interaction diagrams for drug discovery. J Chem Inf
5. Wu W, Cheng Y, Zhou H, Sun C, Zhang S. The SARS-CoV-2 Model. 2011;51:2778-2786.
nucleocapsid protein: Its role in the viral life cycle, structure
and functions, and use as a potential target in the development doi: 10.1021/ci200227u
of vaccines and diagnostics. Virol J. 2023;20(1):6. 17. Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting small-
molecule pharmacokinetic and toxicity properties using
doi: 10.1186/s12985-023-01968-6
graph-based signatures. J Med Chem. 2015;58(9):4066-4072.
6. Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition
by SARS-CoV-2. Nature. 2020;581(7807):221-224. doi: 10.1021/acs.jmedchem.5b00104
18. Elias TC, de Oliveira HC, da Silveira NJ. MB-Isoster:
doi: 10.1038/s41586-020-2179-y
A software for bioisosterism simulation. J Comput Chem.
7. Luty B, Rose PW. The need for scientific software engineering 2018;39(29):2481-2487.
in the pharmaceutical industry. J Comput Aided Mol Des. doi: 10.1002/jcc.25581
2017;31(3):301-304.
19. HU X, Zhou Z, Li F, et al. The study of antiviral drugs
doi: 10.1007/s10822-016-9997-x
targeting SARS-CoV-2 nucleocapsid and spike proteins
8. Lin X, Li X, Lin X. A review on applications of computational through large-scale compound repurposing. Heliyon.
methods in drug screening and design. Molecules. 2021;7(3):e06387.
2020;25(6):1375. doi: 10.1016/j.heliyon.2021.e06387
doi: 10.3390/molecules25061375 20. Chauhan A, Avti P, Shekhar N, et al. Structural and
9. IFPMA: International Federation of Pharmaceutical conformational analysis of SARS CoV 2 N-CTD revealing
Manufacturers and Associations. Facts and Figures 2022. monomeric and dimeric active sites during the RNA-binding
Available from: https://ifpma.org/publications/facts-and- and stabilization: Insights towards potential inhibitors for
figures-2022-the-pharmaceutical-industry-and-global- N-CTD. Comput Biol Med. 2021;134:104495.
health [Last accessed on 2023 Apr 13]. doi: 10.1016/j.compbiomed.2021.104495
10. Surabhi S, Singh BK. Computer aided drug design: An 21. Boniardi I, Corona A, Basquin J, et al. Suramin inhibits
overview. J Drug Deliv Ther. 2018;8(5):504-509. SARS-CoV-2 nucleocapsid phosphoprotein genome
doi: 10.22270/jddt.v8i5.1894 packaging function. Virus Res. 2023;336:199221.
11. Marcelino RC, de Araújo LP, de Morais Borba JR, doi: 10.1016/j.virusres.2023.199221
da Silveira NJ. Molecular docking study involving bioactive 22. Mercaldi GF, Bezerra EH, Batista FA, et al. Discovery and
natural compounds against SARS-CoV-2 proteins. Nat structural characterization of chicoric acid as a SARS-CoV-2
Resour Hum Health. 2022;2:366-377. nucleocapsid protein ligand and RNA binding disruptor. Sci
Rep. 2022;12(1):18500.
doi: 10.53365/nrfhh/147375
doi: 10.1038/s41598-022-22576-4
12. De Morais Borba JR, de Araújo LP, Veloso MP, da Silveira NJ.
Applying the bioisosterism strategy to obtain lead 23. Al-Awar RS, Ray JE, Hecker KA, et al. 1,7-Annulated
compounds against SARS-CoV-2 cysteine proteases: An indolocarbazoles as cyclin-dependent kinase inhibitors.
in-silico approach. J Comput Chem. 2024;45(1):35-46. Bioorg Med Chem Lett. 2004;14(12):3217-3220.
doi: 10.1002/jcc.27217 doi: 10.1016/j.bmcl.2004.03.105

Volume 1 Issue 1 (2024) 124 doi: 10.36922/imo.3731